KR101117673B1 - 암-관련 단백질을 표적으로 하는 알엔에이아이 프로브 - Google Patents

암-관련 단백질을 표적으로 하는 알엔에이아이 프로브 Download PDF

Info

Publication number
KR101117673B1
KR101117673B1 KR1020107028249A KR20107028249A KR101117673B1 KR 101117673 B1 KR101117673 B1 KR 101117673B1 KR 1020107028249 A KR1020107028249 A KR 1020107028249A KR 20107028249 A KR20107028249 A KR 20107028249A KR 101117673 B1 KR101117673 B1 KR 101117673B1
Authority
KR
South Korea
Prior art keywords
cells
sirna
cancer
seq
clu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020107028249A
Other languages
English (en)
Korean (ko)
Other versions
KR20100135335A (ko
Inventor
브르크하르트 얀센
마틴 이. 글리브
막심 시냐프스키
엘리아나 베랄디
이오안니스 피. 트루가코스
에프스타치오스 에스. 고노스
Original Assignee
더 유니버시티 오브 브리티쉬 콜롬비아
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 더 유니버시티 오브 브리티쉬 콜롬비아 filed Critical 더 유니버시티 오브 브리티쉬 콜롬비아
Publication of KR20100135335A publication Critical patent/KR20100135335A/ko
Application granted granted Critical
Publication of KR101117673B1 publication Critical patent/KR101117673B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/712—Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/341—Gapmers, i.e. of the type ===---===
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
KR1020107028249A 2002-08-21 2003-08-21 암-관련 단백질을 표적으로 하는 알엔에이아이 프로브 Expired - Fee Related KR101117673B1 (ko)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US40519302P 2002-08-21 2002-08-21
US60/405,193 2002-08-21
US40815202P 2002-09-03 2002-09-03
US60/408,152 2002-09-03
US47238703P 2003-05-20 2003-05-20
US60/472,387 2003-05-20

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020057002963A Division KR101212512B1 (ko) 2002-08-21 2003-08-21 암-관련 단백질을 표적으로 하는 알엔에이아이 프로브

Publications (2)

Publication Number Publication Date
KR20100135335A KR20100135335A (ko) 2010-12-24
KR101117673B1 true KR101117673B1 (ko) 2012-03-07

Family

ID=31950539

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020107028249A Expired - Fee Related KR101117673B1 (ko) 2002-08-21 2003-08-21 암-관련 단백질을 표적으로 하는 알엔에이아이 프로브
KR1020057002963A Expired - Fee Related KR101212512B1 (ko) 2002-08-21 2003-08-21 암-관련 단백질을 표적으로 하는 알엔에이아이 프로브
KR1020117025408A Expired - Fee Related KR101238701B1 (ko) 2002-08-21 2003-08-21 암-관련 단백질을 표적으로 하는 알엔에이아이 프로브

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020057002963A Expired - Fee Related KR101212512B1 (ko) 2002-08-21 2003-08-21 암-관련 단백질을 표적으로 하는 알엔에이아이 프로브
KR1020117025408A Expired - Fee Related KR101238701B1 (ko) 2002-08-21 2003-08-21 암-관련 단백질을 표적으로 하는 알엔에이아이 프로브

Country Status (10)

Country Link
US (5) US8252918B2 (enExample)
EP (2) EP1532249A2 (enExample)
JP (4) JP4717633B2 (enExample)
KR (3) KR101117673B1 (enExample)
AU (1) AU2003258426B2 (enExample)
CA (2) CA2494766C (enExample)
IL (3) IL166658A (enExample)
NO (2) NO334573B1 (enExample)
NZ (1) NZ552872A (enExample)
WO (1) WO2004018676A2 (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ513757A (en) 1999-02-26 2004-12-24 Univ British Columbia Antisense oligonucleotides to inhibit TRPM-2 expression and delay androgen independance in prostatic tumour cells
US7569551B2 (en) 2000-02-25 2009-08-04 The University Of British Columbia Chemo- and radiation-sensitization of cancer by antisense TRPM-2 oligodeoxynucleotides
WO2003062421A1 (en) 2002-01-17 2003-07-31 The University Of British Columbia Bispecific antisense olignucleotides that inhibit igfbp-2 and igfbp-5 and methods of using same
US7285541B2 (en) 2002-08-21 2007-10-23 The University Of British Columbia Treatment of melanoma by reduction in clusterin levels
KR101117673B1 (ko) * 2002-08-21 2012-03-07 더 유니버시티 오브 브리티쉬 콜롬비아 암-관련 단백질을 표적으로 하는 알엔에이아이 프로브
US7635673B2 (en) 2003-03-25 2009-12-22 The Board Of Trustees Of The University Of Illinois Methods of inhibiting tumor cell proliferation
US20040220131A1 (en) * 2003-04-18 2004-11-04 The University Of British Columbia Method for treatment of cancerous angiogenic disorders
US20050019918A1 (en) * 2003-06-03 2005-01-27 Hidetoshi Sumimoto Treatment of cancer by inhibiting BRAF expression
JP2005013221A (ja) * 2003-06-03 2005-01-20 Keio Gijuku Ｂｒａｆ発現抑制を利用した癌の治療
MXPA06010667A (es) * 2004-03-19 2007-07-04 Penn State Res Found Metodos combinatorios y composiciones para el tratamiento de melanoma.
US8710020B2 (en) 2004-04-02 2014-04-29 The University Of British Columbia Clusterin antisense therapy for treatment of cancer
ATE501252T1 (de) * 2004-06-22 2011-03-15 Univ Illinois Verfahren zur inhibierung von tumorzellwachstum mit foxm1 sirns
AU2005266948A1 (en) * 2004-07-23 2006-02-02 Pacific Edge Biotechnology Ltd. Urine markers for detection of bladder cancer
WO2006035432A2 (en) * 2004-09-27 2006-04-06 Tel Hashomer Medical Research Infrastructure And Services Ltd. Gene silencing for use in dermatology
SI1814595T1 (sl) * 2004-11-23 2014-06-30 The University Of British Columbia Zdravljenje raka s kombinacijo sredstva, ki moti EGF signalno pot, in oligonukleotida, ki zniĹľuje nivoje klusterina
ES2543341T3 (es) 2005-09-13 2015-08-18 National Research Council Of Canada Métodos y composiciones para modular la actividad de células tumorales
US8029980B2 (en) 2006-09-29 2011-10-04 The Board Of Trustees Of The University Of Illinois Identification and use of agents that modulate oncogenic transcription agent activity
JP2010517941A (ja) * 2007-01-16 2010-05-27 ザ バーナム インスティテュート フォー メディカル リサーチ 結腸直腸癌の治療のための組成物および方法
US8071752B2 (en) * 2007-01-29 2011-12-06 City Of Hope Multi-targeting short interfering RNAs
WO2008109361A1 (en) * 2007-03-02 2008-09-12 Mdrna, Inc, Nucleic acid compounds for inhibiting erbb family gene expression and uses thereof
US8217161B2 (en) * 2008-04-22 2012-07-10 Clemson University Research Foundation Methods of inhibiting multiple cytochrome P450 genes with siRNA
CA2928846A1 (en) 2009-11-24 2011-06-03 Alethia Biotherapeutics Inc. Anti-clusterin antibodies and antigen binding fragments and their use to reduce tumor volume
EP3604534A1 (en) 2011-02-11 2020-02-05 The Rockefeller University Method for identifying nucleic acids regulating metastasation
CA2862739A1 (en) 2012-02-22 2013-08-29 Alethia Biotherapeutics Inc. Co-use of a clusterin inhibitor with an egfr inhibitor to treat cancer
CA2844640A1 (en) 2013-12-06 2015-06-06 The University Of British Columbia Method for treatment of castration-resistant prostate cancer
CN106282185B (zh) * 2016-08-18 2020-06-26 广州市锐博生物科技有限公司 一种用于抑制簇集蛋白基因表达的成套siRNA及其应用
KR102923964B1 (ko) 2023-04-13 2026-02-09 한양대학교 에리카산학협력단 Igfbp5 돌연변이체 또는 이를 발현하는 벡터를 유효성분으로 포함하는 암 예방 또는 치료용 약학적 조성물
WO2024214933A1 (ko) * 2023-04-13 2024-10-17 한양대학교 에리카산학협력단 인산화된 igfbp5의 과도한 생성을 차단하여 암을 예방 또는 치료하는 방법
WO2025041340A1 (ja) * 2023-08-24 2025-02-27 株式会社Dti 二重特異性核酸

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5736580A (en) * 1980-08-13 1982-02-27 Hitachi Ltd Protecting method for converter
CA2108144A1 (en) 1991-03-06 1992-09-07 Jack A. Roth Methods and compositions for the selective inhibition of gene expression
AUPM672594A0 (en) * 1994-07-08 1994-08-04 Royal Children's Hospital Research Foundation A method for the prophylaxis and/or treatment of proliferative and/or inflammatory skin disorders
US20020086386A1 (en) * 1997-03-04 2002-07-04 Kamb Carl Alexander B-catenin assays, and compositions therefrom
US6383808B1 (en) * 2000-09-11 2002-05-07 Isis Pharmaceuticals, Inc. Antisense inhibition of clusterin expression
NZ513757A (en) 1999-02-26 2004-12-24 Univ British Columbia Antisense oligonucleotides to inhibit TRPM-2 expression and delay androgen independance in prostatic tumour cells
WO2000069454A1 (en) * 1999-05-17 2000-11-23 Board Of Regents, The University Of Texas System Suppression of endogenous igfbp-2 to inhibit cancer
ATE393220T1 (de) * 1999-07-19 2008-05-15 Univ British Columbia Antisense-therapie für hormonregulierte tumoren
US6140126A (en) * 1999-10-26 2000-10-31 Isis Pharmaceuticals Inc. Antisense modulation of Y-box binding protein 1 expression
GB9927444D0 (en) * 1999-11-19 2000-01-19 Cancer Res Campaign Tech Inhibiting gene expression
US7569551B2 (en) 2000-02-25 2009-08-04 The University Of British Columbia Chemo- and radiation-sensitization of cancer by antisense TRPM-2 oligodeoxynucleotides
JP2003526367A (ja) * 2000-03-16 2003-09-09 ジェネティカ インコーポレイテッド Ｒｎａ干渉の方法とｒｎａ干渉組成物
KR20080023768A (ko) * 2000-03-30 2008-03-14 화이트헤드 인스티튜트 포 바이오메디칼 리서치 Ｒｎａ 간섭의 ｒｎａ 서열 특이적인 매개체
US7196067B2 (en) 2000-09-14 2007-03-27 The University Of British Columbia Antisense insulin-like growth factor binding protein (IGFBP)-2-oligodeoxynucleotides for prostate and other endocrine tumor therapy
CN100523215C (zh) * 2000-12-01 2009-08-05 马普科技促进协会 介导rna干涉的小rna分子
JP2004532616A (ja) 2000-12-28 2004-10-28 ジョンソン・アンド・ジョンソン・リサーチ・ピー・ティー・ワイ・リミテッド 二本鎖ｒｎａ仲介遺伝子抑制
EP1386004A4 (en) * 2001-04-05 2005-02-16 Ribozyme Pharm Inc MODULATION OF GENE EXPRESSION ASSOCIATED WITH INFLAMMATORY PROLIFERATION AND GROWTH OF NEURITIES BY METHODS INVOLVING NUCLEIC ACID
WO2003062421A1 (en) * 2002-01-17 2003-07-31 The University Of British Columbia Bispecific antisense olignucleotides that inhibit igfbp-2 and igfbp-5 and methods of using same
US7285541B2 (en) 2002-08-21 2007-10-23 The University Of British Columbia Treatment of melanoma by reduction in clusterin levels
KR101117673B1 (ko) * 2002-08-21 2012-03-07 더 유니버시티 오브 브리티쉬 콜롬비아 암-관련 단백질을 표적으로 하는 알엔에이아이 프로브
US7250496B2 (en) * 2002-11-14 2007-07-31 Rosetta Genomics Ltd. Bioinformatically detectable group of novel regulatory genes and uses thereof
EP2305813A3 (en) * 2002-11-14 2012-03-28 Dharmacon, Inc. Fuctional and hyperfunctional sirna

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Curr Opin Chem Biol, Vol. 6, pp. 829-834 (2002)
Genes Dev, Vol. 16, pp. 948-958 (2002)
J. Pathol., Vol. 183, pp. 345-351 (1997)

Also Published As

Publication number Publication date
EP2263679A2 (en) 2010-12-22
IL197159A (en) 2016-11-30
US7964717B2 (en) 2011-06-21
NZ552872A (en) 2007-11-30
US20080274996A1 (en) 2008-11-06
JP2011036267A (ja) 2011-02-24
KR20050042483A (ko) 2005-05-09
JP2013150624A (ja) 2013-08-08
KR101238701B1 (ko) 2013-03-05
US20110009472A1 (en) 2011-01-13
US20120202873A1 (en) 2012-08-09
NO334573B1 (no) 2014-04-14
JP5171887B2 (ja) 2013-03-27
KR101212512B1 (ko) 2012-12-26
JP2010193908A (ja) 2010-09-09
WO2004018676A2 (en) 2004-03-04
US20040096882A1 (en) 2004-05-20
US8252918B2 (en) 2012-08-28
AU2003258426A1 (en) 2004-03-11
EP1532249A2 (en) 2005-05-25
KR20100135335A (ko) 2010-12-24
AU2003258426B2 (en) 2008-04-10
CA2494766C (en) 2015-05-12
JP4717633B2 (ja) 2011-07-06
JP5662766B2 (ja) 2015-02-04
IL166658A0 (en) 2006-01-15
CA2882443A1 (en) 2004-03-04
US20060178329A1 (en) 2006-08-10
NO337130B1 (no) 2016-01-25
JP2006500958A (ja) 2006-01-12
US7820635B2 (en) 2010-10-26
NO20121038L (no) 2005-05-20
IL166658A (en) 2014-11-30
WO2004018676A3 (en) 2004-08-12
CA2882443C (en) 2016-12-13
IL197159A0 (en) 2011-07-31
IL233352A0 (en) 2014-08-31
US8759308B2 (en) 2014-06-24
EP2263679B1 (en) 2014-10-08
EP2263679A3 (en) 2011-10-12
NO20051423L (no) 2005-05-20
KR20110122883A (ko) 2011-11-11
US9487777B2 (en) 2016-11-08
CA2494766A1 (en) 2004-03-04

Similar Documents

Publication Publication Date Title
KR101238701B1 (ko) 암-관련 단백질을 표적으로 하는 알엔에이아이 프로브
EP1490490B1 (en) Antisense iap nucleobase oligomers and uses thereof
AU2003258425B2 (en) Treatment of melanoma by reduction in clusterin levels
WO2021152005A1 (en) Antisense oligonucleotide targeting linc00518 for treating melanoma
AU2007216630B2 (en) RNAi probes targeting cancer-related proteins
NZ538287A (en) RNAi probes targeting cancer-related proteins

Legal Events

Date Code Title Description
A107 Divisional application of patent
A201 Request for examination
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A16-div-PA0104

St.27 status event code: A-0-1-A10-A18-div-PA0104

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

J201 Request for trial against refusal decision
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PJ0201 Trial against decision of rejection

St.27 status event code: A-3-3-V10-V11-apl-PJ0201

PB0901 Examination by re-examination before a trial

St.27 status event code: A-6-3-E10-E12-rex-PB0901

B701 Decision to grant
PB0701 Decision of registration after re-examination before a trial

St.27 status event code: A-3-4-F10-F13-rex-PB0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

Fee payment year number: 1

St.27 status event code: A-2-2-U10-U12-oth-PR1002

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

FPAY Annual fee payment

Payment date: 20150127

Year of fee payment: 4

PR1001 Payment of annual fee

Fee payment year number: 4

St.27 status event code: A-4-4-U10-U11-oth-PR1001

FPAY Annual fee payment

Payment date: 20160125

Year of fee payment: 5

PR1001 Payment of annual fee

Fee payment year number: 5

St.27 status event code: A-4-4-U10-U11-oth-PR1001

PR1001 Payment of annual fee

Fee payment year number: 6

St.27 status event code: A-4-4-U10-U11-oth-PR1001

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

Not in force date: 20180211

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

St.27 status event code: A-4-4-U10-U13-oth-PC1903

PC1903 Unpaid annual fee

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20180211

St.27 status event code: N-4-6-H10-H13-oth-PC1903